In preclinical neuroblastoma models, iNKT eliminate CD1d-expressing TAM and inhibit the function of myeloid-derived suppressor cells (MDSC) in a CD1d- and CD40-dependent manner, thereby creating a more favorable microenvironment for effector immune responses (23, 43, 44). The gene discussed is CD1D; the disease is neuroblastoma.